In the BioHarmony Drug Report Database

"Preview" Icon

Rimegepant

Nurtec Odt (rimegepant) is a small molecule pharmaceutical. Rimegepant was first approved as Nurtec Odt on 2020-02-27. It is used to treat migraine disorders, migraine with aura, and migraine without aura in the USA. The pharmaceutical is active against calcitonin gene-related peptide type 1 receptor. Nurtec odt’s patents are valid until 2039-03-25 (FDA).

 

Trade Name

 

Nurtec Odt
 

Common Name

 

rimegepant
 

ChEMBL ID

 

CHEMBL2178422
 

Indication

 

migraine disorders, migraine with aura, migraine without aura
 

Drug Class

 

Calcitonin gene-related peptide receptor antagonists

Image (chem structure or protein)

Rimegepant structure rendering